max為實(shí)測(cè)值,AUC計(jì)算采用梯形法。結(jié)果:康萊特注射液10、5 mL/kg劑量的主要藥動(dòng)學(xué)參數(shù):Cmax分別為(8.532±1.031)、(5.418±0.764)mmol/L,AUC0-t分別為(13.248±3.692)、(5.339±1.219)mmol/L?h,Vc分別為(1.030±0.131)、(0.756±0.150)L2/(kg·mol),CLs分別為(0.838±0.319)、(0.975±0.330)L2/(kg·mol·h),t 1/2α 分別為(0.481±0.168)、(0.322±0.109)h,t 1/2β分別為(1.452±0.776)、(1.384±0.404)h。結(jié)論:康萊特注射液經(jīng)尾iv給藥后在大鼠體內(nèi)的藥動(dòng)學(xué)過(guò)程經(jīng)擬合為二室模型。;Objective: To study the in vivo pharmacokinetics of Kanglaite Injection in rats. Methods: The concentration change of exogenous triglyceride (TG) in rat serum was detected by TG Kit after iv administration of Kanglaite Injection in tail. The concentration of exogenous TG was the concentration after the background subtraction. Pharmacokinetic parameters were calculated by 3P97 software. Cmax was the true value, AUC is obtained by the trapezoidal rule. Results: At the dosages of 10 and 5 mL/kg the main pharmacokinetic parameters of Kanglaite Injection were as follows: Cmax=(8.532 ± 1.031) and (5.418 ± 0.764) mmol/L, AUC0-t=(13.248 ± 3.692) and (5.339 ± 1.219) mmol/L?h, Vc=(1.030 ± 0.131) and (0.756± 0.150) L2/(kg·mol), CLs=(0.838 ± 0.319) and (0.975 ± 0.330) L2/(kg·mol·h), t 1/2 α=(0.481 ± 0.168) and (0.322 ± 0.109) h, t 1/2 β=(1.452 ± 0.776) and (1.384 ± 0.404)h. Conclusion:The in vivo pharmacokinetic model of Kanglaite Injection after iv injection in rat tail is two compartment model."/>
醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费
大鼠靜脈注射康萊特注射液的藥動(dòng)學(xué)研究
Pharmacokinetics of Kanglaite Injection by intravenousadministration in rats
藥物評(píng)價(jià)研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號(hào)
互聯(lián)網(wǎng)藥品信息服務(wù)資格證書(shū)編號(hào):(津)-非經(jīng)營(yíng)性-2015-0031